Figure 1.
Abnormal expression of CD39 and CD73 on malignant and nonmalignant circulating lymphocytes of patients with SS. Expression of CD39 and CD73 was assessed on total blood of patients with SS (n = 37) or healthy donors (HD; n = 49) by flow cytometry. After acquisition on a flow cytometer, the percentage of CD39+ and/or CD73+ cells was estimated on (A) HD (CD3+CD4+) or SS total (CD3+CD4+), malignant (CD3+TCRVβ+CD4+) or nonmalignant (CD3+TCRVβ-CD4+) CD4+ T cells, (D) NK cells (CD3−CD56+) and (E) B cells (CD3−CD19+). (B) Histograms showing CD39 and CD73 single (SP) or double (DP) expression by normal (HD) or malignant/nonmalignant (SS) CD4+ T cells of each donor tested in each group. (A,C-E) Statistical analysis was performed using a Mann-Whitney t test. **P < .01, ***P < .001, ****P < .0001.

Abnormal expression of CD39 and CD73 on malignant and nonmalignant circulating lymphocytes of patients with SS. Expression of CD39 and CD73 was assessed on total blood of patients with SS (n = 37) or healthy donors (HD; n = 49) by flow cytometry. After acquisition on a flow cytometer, the percentage of CD39+ and/or CD73+ cells was estimated on (A) HD (CD3+CD4+) or SS total (CD3+CD4+), malignant (CD3+TCRVβ+CD4+) or nonmalignant (CD3+TCRVβ-CD4+) CD4+ T cells, (D) NK cells (CD3−CD56+) and (E) B cells (CD3−CD19+). (B) Histograms showing CD39 and CD73 single (SP) or double (DP) expression by normal (HD) or malignant/nonmalignant (SS) CD4+ T cells of each donor tested in each group. (A,C-E) Statistical analysis was performed using a Mann-Whitney t test. **P < .01, ***P < .001, ****P < .0001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal